Publikationen suchen
- Publikation
- Autoren
- Einrichtungen
- Abstract
- Externe Dokumente
- Links
Final results from a randomised phase II study comparing epirubicin plus cyclophosphamide (EC) or CMF versus nab-paclitaxel plus capecitabine (PX) as adjuvant chemotherapy for elderly non-frail breast cancer patients with an increased risk of relapse
(
Zeitschriftenartikel
)